Characterization of basal and morphine-induced histamine release in the rat periaqueductal gray

J Neurochem. 1994 Jul;63(1):238-44. doi: 10.1046/j.1471-4159.1994.63010238.x.

Abstract

Previous studies have shown that antinociceptive doses of systemic morphine increase extracellular histamine (HA) levels in the rat periaqueductal gray (PAG), although the cellular origin of basal and morphine-induced HA release in the PAG is unknown. Treatment with alpha-fluoromethylhistidine (FMH; 100 mg/kg, i.p.), the irreversible inhibitor of histidine decarboxylase, decreased basal HA release by a maximum of 80% and prevented morphine-induced HA release in the PAG. In addition, perfusion of this area with the sodium channel blocker tetrodotoxin (10(-6) M) decreased basal HA release by a maximum of 57% from baseline levels. When the perfusion medium was modified by substitution of magnesium for calcium, extracellular HA levels in the PAG decreased by a maximum of 72%, and morphine-induced HA release was prevented. Thioperamide (5 mg/kg, i.p.), an H3 antagonist, increased HA release in the PAG to a maximum of 249% within the first 30-60-min period. Taken together, these results suggest that basal and morphine-induced HA release in the rat PAG have a neuronal origin.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Anticonvulsants / pharmacology
  • Histamine Release / drug effects*
  • Histidine Decarboxylase / antagonists & inhibitors
  • Male
  • Methylhistidines / pharmacology
  • Morphine / pharmacology*
  • Periaqueductal Gray / metabolism*
  • Piperidines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Tetrodotoxin / pharmacology

Substances

  • Anticonvulsants
  • Methylhistidines
  • Piperidines
  • Tetrodotoxin
  • alpha-fluoromethylhistidine
  • Morphine
  • Histidine Decarboxylase
  • thioperamide